Lannett Company, Inc. (LCI)

NYSE: LCI · IEX Real-Time Price · USD
0.620
+0.010 (1.64%)
At close: Dec 2, 2022 4:00 PM
0.680
+0.060 (9.68%)
After-hours: Dec 2, 2022 7:30 PM EST
1.64%
Market Cap 23.92M
Revenue (ttm) 314.13M
Net Income (ttm) -237.30M
Shares Out 40.94M
EPS (ttm) -7.89
PE Ratio n/a
Forward PE 16.39
Dividend n/a
Ex-Dividend Date n/a
Volume 100,056
Open 0.645
Previous Close 0.61
Day's Range 0.601 - 0.7
52-Week Range 0.385 - 2.16
Beta 0.94
Analysts Sell
Price Target 1.02 (+64.5%)
Earnings Date Nov 2, 2022

About LCI

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular,... [Read more]

Industry Pharmaceuticals
Founded 1942
CEO Timothy Crew
Employees 564
Stock Exchange NYSE
Ticker Symbol LCI
Full Company Profile

Financial Performance

In 2022, LCI's revenue was $340.58 million, a decrease of -28.86% compared to the previous year's $478.78 million. Losses were -$231.62 million, -36.28% less than in 2021.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for LCI stock is "Sell." The 12-month stock price forecast is 1.02, which is an increase of 64.52% from the latest price.

Price Target
$1.02
(64.52% upside)
Analyst Consensus: Sell
Stock Forecasts

News

LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULI...

TREVOSE, Pa. , Nov. 7, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector dev...

4 weeks ago - PRNewsWire

Lannett (LCI) Reports Q1 Loss, Tops Revenue Estimates

Lannett (LCI) delivered earnings and revenue surprises of 8.70% and 10.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

LANNETT REPORTS BETTER THAN EXPECTED FINANCIAL RESULTS FOR FISCAL 2023 FIRST-QUARTER; REITERATES FULL-YEAR GUIDANCE

Q1 Business and Financial Highlights: Net Sales were $75.1 Million Gross Margin 17%, Adjusted Gross Margin 18% Net Sales, Gross Margin and Adjusted Gross Margin Increased from Preceding Quarter Cash Was...

1 month ago - PRNewsWire

LANNETT TO REPORT FISCAL 2023 FIRST-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2

TREVOSE, Pa. , Oct. 26, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2023 first quarter on Wednesday, November 2, 2022, aft...

1 month ago - PRNewsWire

LANNETT RECEIVES FDA APPROVAL TO MANUFACTURE NUMBRINO® AT SEYMOUR PLANT

--Approval Allows Site to Rapidly Expand Liquid Drug Manufacturing-- PHILADELPHIA , Oct. 21, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the...

1 month ago - PRNewsWire

LANNETT ANNOUNCES SALE OF SEVERAL DISCONTINUED GENERIC DRUGS

-Companies Entered Into a Separate Private Label Agreement for Certain Other Lannett Generic Products- PHILADELPHIA , Oct. 19, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that...

1 month ago - PRNewsWire

LANNETT ANNOUNCES SUBJECT DOSING COMPLETE FOR PIVOTAL CLINICAL TRIAL OF BIOSIMILAR INSULIN GLARGINE

No Reported Serious Adverse Events; Topline Results Expected Later This Year TREVOSE, Pa. , Aug. 31, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that subject dosing has been c...

3 months ago - PRNewsWire

LANNETT REPORTS FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS

Q4 Business and Financial Highlights: Net Sales were $74.2 Million Adjusted Gross Margin Better than Expected, Improved vs Q3 Cash Was $88 Million at June 30 Completed Major Elements of November 2021 Re...

3 months ago - PRNewsWire

LANNETT TO REPORT FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, AUGUST 24

TREVOSE, Pa. , Aug. 19, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 fourth quarter and full year on Wednesday, August...

3 months ago - PRNewsWire

LANNETT PROVIDES UPDATE ON PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE

Approximately Half of the Planned Number of Subjects Have Received the First Dose, With No Reported Serious Adverse Events Study Progressing On Schedule Topline Results Expected Later This Year TREVOSE,...

6 months ago - PRNewsWire

LANNETT ENTERS AGREEMENT TO BE EXCLUSIVE U.S. DISTRIBUTOR OF FLUDARABINE PHOSPATE FOR INJECTION, USP

-- Current Drug Market Shortage Exists for Fludarabine Phosphate, An Injectable Chemotherapeutic Medication; Marketing Anticipated to Commence Later This Calendar Year --  PHILADELPHIA, May 12, 2022 /PR...

6 months ago - PRNewsWire

Lannett (LCI) Reports Q3 Loss, Lags Revenue Estimates

Lannett (LCI) delivered earnings and revenue surprises of 4.65% and 6.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

LANNETT REPORTS FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS

Q3 Business and Financial Highlights: Net Sales were $78.4 Million Cash in Excess of $106 Million at March 31 Completed Sale of Liquid Manufacturing Plant for $10.5 Million; Major Elements of November 2...

7 months ago - PRNewsWire

LANNETT TO REPORT FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, MAY 4

TREVOSE, Pa. , April 27, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 third quarter on Wednesday, May 4, 2022, after t...

7 months ago - PRNewsWire

LANNETT INITIATES PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE

--First Patient Dosed, Topline Study Results Expected Later This Year; Potential BLA Filing in Early 2023 and Launch in the First Half of 2024-- TREVOSE, Pa. , March 29, 2022 /PRNewswire/ -- Lannett Com...

8 months ago - PRNewsWire

LANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-COMPLIANCE FROM NYSE RELATED TO STOCK PRICE

TREVOSE, Pa. , March 18, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has received written notice from the New York Stock Exchange (NYSE) dated March 14, 2022, notifyin...

8 months ago - PRNewsWire

LANNETT TO PRESENT AT THE 34th ANNUAL ROTH CONFERENCE ON MARCH 14

TREVOSE, Pa., March 4, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that the company will participate in a fireside chat at the 34th Annual ROTH Conference on March 14, 2022 at...

9 months ago - PRNewsWire

LANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-COMPLIANCE FROM NYSE

TREVOSE, Pa., March 4, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has received written notice from the New York Stock Exchange (NYSE) dated March 2, 2022, notifying t...

9 months ago - PRNewsWire

LANNETT Announces sale of liquid drug manufacturing plant and other assets for $10.5 million

PHILADELPHIA, March 4, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into material definitive agreements to sell its liquid drug manufacturing facility in Ca...

9 months ago - PRNewsWire

Lannett's Q2 Sales, Profit Hit By Pricing Pressures, Lowers FY22 Outlook

Lannett Company Inc LCI reported Q2 FY22 sales of $86.51 million, missing the consensus of $90.21 million. Sales decreased 35% Y/Y as Lannett faced a highly competitive pricing environment.

10 months ago - Benzinga

Lannett (LCI) Reports Q2 Loss, Misses Revenue Estimates

Lannett (LCI) delivered earnings and revenue surprises of -21.88% and 14.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

LANNETT REPORTS FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS; REVISES DOWN FULL-YEAR GUIDANCE

TREVOSE, Pa., Feb. 3, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2022 second quarter ended December 31, 2021.

10 months ago - PRNewsWire

LANNETT TO REPORT FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON THURSDAY, FEBRUARY 3

TREVOSE, Pa., Jan. 27, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 second quarter on Thursday, February 3, 2022, afte...

10 months ago - PRNewsWire

Earnings Preview: Lannett (LCI) Q2 Earnings Expected to Decline

Lannett (LCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 months ago - Zacks Investment Research

LANNETT ANNOUNCES FDA COMPLETES REVIEW OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE

PHILADELPHIA, Jan. 21, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that they have completed the safet...

10 months ago - PRNewsWire